Recovery of systolic dysfunction in duchenne muscular dystrophy due to the point mutation c.4213c>t

Cardiology

Volumn 117, Issue 4, 2011, Pages 265-267

  Finsterer, Josef ^a   Stöllberger, Claudia ^a   Holinski Feder, Elke ^b  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b Medizinisch Genetisches Zentrum   (Germany)

Author keywords

Cardiac involvement; Dystrophin; Heart failure; Muscular dystrophy; Point mutation; Systolic dysfunction

Indexed keywords

BISOPROLOL; DYSTROPHIN; ENALAPRIL;

ADULT; ANKLE; ARTICLE; CASE REPORT; CERVICAL SPINE; CHINESE; CONTRACTURE; DRUG DOSE INCREASE; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; EXON; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HYPOTENSION; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; OUTCOME ASSESSMENT; POINT MUTATION; PRIORITY JOURNAL; REFLEX DISORDER; RENAL IMPAIRMENT; SINUS RHYTHM; ST SEGMENT ELEVATION; SYSTOLIC DYSFUNCTION;

ADULT; ANTIHYPERTENSIVE AGENTS; BISOPROLOL; DRUG THERAPY, COMBINATION; ENALAPRIL; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; POINT MUTATION; SYSTOLE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79151475205     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323515     Document Type: Article

References (10)

1. Kajimoto H, Ishigaki K, Okumura K, Tomimatsu H, Nakazawa M, Saito K, Osawa M, Nakanishi T: Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J 2006; 70: 991-994. (Pubitemid 44161734)
2. Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, Neish SR, Smith EO, Towbin JA: Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005; 112: 2799-2804. (Pubitemid 41641674)
3. Ishikawa Y, Bach JR, Minami R: Cardioprotection for Duchenne's muscular dystrophy. Am Heart J 1999; 137: 895-902. (Pubitemid 29226300)
4. Bouhouch R, Elhouari T, Oukerraj L, Fellat I, Zarzur J, Bennani R, Arharbi M: Management of cardiac involvement in neuromuscular diseases. Open Cardiovasc Med J 2008; 2: 93-96.
5. Ramaciotti C, Heistein LC, Coursey M, Lemler MS, Eapen RS, Iannaccone ST, Scott WA: Left ventricular function and response to enalapril in patients with Duchenne muscular dystrophy during the second decade of life. Am J Cardiol 2006; 98: 825-827. (Pubitemid 44301021)
6. Ogata H, Ishikawa Y, Ishikawa Y, Minami R: Beneficial effects of beta-blockers and angiotensin- converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol 2009; 53: 72-78.
7. Bushby K, Muntoni F, Bourke JP: 107th ENMC international workshop: The management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 2003; 13: 166-172. (Pubitemid 36140013)
8. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, Berard C, Vaksmann G, Weber S, Bécane HM: Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007; 154: 596-602. (Pubitemid 47268252)
9. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Bécane HM: Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005; 45: 855-857. (Pubitemid 40342808)
10. Stöllberger C, Finsterer J: Can perindopril delay the onset of heart failure in Duchenne muscular dystrophy? J Am Coll Cardiol 2005; 46: 1781.